Quarterly report [Sections 13 or 15(d)]

NON CONTROLLING INTEREST (Tables)

NON CONTROLLING INTEREST (Tables)

3 Months Ended

Mar. 31, 2026

ROYALTY OBLIGATIONS NET

Schedule of net loss attributable to non-controlling interest

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(118,452	)		$	(10	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(28,665	)		$	(3	)

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(42,784	)		$	(10	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(10,354	)		$	(3	)

Schedule of changes in non-controlling interest

Balance, December 31, 2025		$	(303,429	)
Net loss attributable to the non-controlling interest			(28,665	)
Acquisition of non-controlling interest by the Company			158,835
Balance, March 31, 2026			(173,259	)

Balance, December 31, 2024		$	(234,812	)
Net loss attributable to the non-controlling interest			(10,357	)
Balance, March 31, 2025			(245,169	)